Bausch + Lomb shares are trading lower after the company announced that its Phase 2 trial evaluating BL1107 in patients with glaucoma failed to meet its primary endpoint.

Benzinga News-desk www.benzinga.com Negative 97.2%

Neg 97.2% Neu 0% Pos 0%

Comments

No comments yet. Be the first!